pre-update Archives

On-Demand Webinar

Part 1: What are oligonucleotide therapeutics, and how do they work?

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Plan to Accelerate Your Time to Drug Submissions

There are common themes driving how quickly you can get from your last database lock…

CertaraApril 20, 2021

On-Demand Webinar

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Pediatric PBPK models have broad application in the drug development process and are being used…

CertaraApril 20, 2021

White Paper

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Do expensive bioequivalence studies stall your generic drug approval? Learn how you can streamline complex…

CertaraApril 15, 2021

Publication

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…

CertaraApril 8, 2021

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

CertaraApril 1, 2021

Press Coverage

Legislators: Bring all stakeholders to the table to lower drug costs

BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the…

CertaraMarch 30, 2021

On-Demand Webinar

Strategic Evidence & Value Communication Symposium

Join us on Wednesday, April 21, 2021, from12:00 PM – 2:00 PM EDT for Certara’s…

CertaraMarch 26, 2021

Brochure

Leveraging a Compliant Data Repository to Significantly Improve Biostatistics Workflow

CertaraMarch 25, 2021

On-Demand Webinar

Purity is a Virtue: A Practical Guide to the Reporting of Impurities

Many pharmaceutical companies struggle with characterizing drug substance (DS) and drug product (DP) impurities and…

CertaraMarch 23, 2021

pre-update

Part 1: What are oligonucleotide therapeutics, and how do they work?

Plan to Accelerate Your Time to Drug Submissions

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

Legislators: Bring all stakeholders to the table to lower drug costs

Strategic Evidence & Value Communication Symposium

Leveraging a Compliant Data Repository to Significantly Improve Biostatistics Workflow

Purity is a Virtue: A Practical Guide to the Reporting of Impurities

Newsletter sign up

Quick links

Solutions

Contact